Disease: Steatohepatitis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE We also report the finding that steatosis abrogates hepatic LDLR expression and increases circulating LDL levels in a PCSK9-dependent manner. 31004037 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE Circulating PCSK9 levels are closely related to hepatic steatosis severity and endogenous estrogen levels. 31085239 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 Biomarker disease BEFREE Circulating PCSK9 concentrations are not associated with the severity of liver steatosis or histological markers of NASH. 30261472 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE Thus, it is evident that sauchinone reduces hepatic steatosis by downregulating the expression of hepatic PCSK9 via SREBP-2. 29712938 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 GeneticVariation disease BEFREE A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease. 28711549 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 GeneticVariation disease BEFREE Methods Subjects from the PLIC cohort were genotyped for the loss-of-function PCSK9 R46L variant and characterized for clinical and biochemical parameters, total and android fat mass, hepatic steatosis and epicardial fat thickness. 28758421 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE PCSK9 mRNA levels were also correlated with steatosis severity (p = 0.04) and hepatic APOB (p < 0.001), SREBP-1c (p = 0.047) and FAS expression (p = 0.001). 27222915 2016
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 Biomarker disease HPO